Activities of Acyclic Nucleoside Phosphonates Against Orf Virus in Human and Ovine Cell Monolayers and Organotypic Ovine Raft Cultures

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2005 Nov 24

PMID 16304144

Citations 13

Authors

F Dal Pozzo

G Andrei

A Holy

J van den Oord

A Scagliarini

E De Clercq

R Snoeck

Affiliations

Soon will be listed here.

Abstract

Orf virus, a member of the Parapoxvirus genus, causes a contagious pustular dermatitis in sheep, goats, and humans. Previous studies have demonstrated the activity of (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (HPMPC; cidofovir; Vistide) against orf virus in cell culture and humans. We have evaluated a broad range of acyclic nucleoside phosphonates (ANPs) against several orf virus strains in primary lamb keratinocytes (PLKs) and human embryonic lung (HEL) monolayers. HPMPC, (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6- diaminopurine (HPMPDAP), and (R)-9-[3-hydroxy-2-(phosphonomethoxy)propoxy]-2,4-diaminopyrimidine (HPMPO-DAPy) were three of the most active compounds that were subsequently tested in a virus yield assay with PLK and HEL cells by virus titration and DNA quantification. HPMPC, HPMPDAP, and HPMPO-DAPy were evaluated for their activities against orf virus replication in organotypic epithelial raft cultures from differentiated PLK cells. At the highest concentrations (50 and 20 microg/ml), full protection was provided by the three drugs, while at 5 microg/ml, only HPMPDAP and HPMPC offered partial protection. The activities of the three compounds in the raft culture system were confirmed by quantification of infectious virus and viral DNA. These findings provide a rationale for the use of HPMPC and other ANPs in the treatment of orf (contagious ecthyma) in humans and animals.

Citing Articles

Genistein is effective in inhibiting Orf virus infection by targeting viral RNA polymerase subunit RPO30 protein.

Lv P, Fang Z, Guan J, Lv L, Xu M, Liu X Front Microbiol. 2024; 15:1336490.

PMID: 38389526 PMC: 10882098. DOI: 10.3389/fmicb.2024.1336490.

Poxviruses Bearing DNA Polymerase Mutations Show Complex Patterns of Cross-Resistance.

Andrei G, Fiten P, Krecmerova M, Opdenakker G, Topalis D, Snoeck R Biomedicines. 2022; 10(3).

PMID: 35327382 PMC: 8945813. DOI: 10.3390/biomedicines10030580.

Overview of Biologically Active Nucleoside Phosphonates.

Groaz E, De Jonghe S Front Chem. 2021; 8:616863.

PMID: 33490040 PMC: 7821050. DOI: 10.3389/fchem.2020.616863.

Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses.

De Clercq E Adv Antivir Drug Des. 2020; 5:1-58.

PMID: 32288472 PMC: 7146823. DOI: 10.1016/S1075-8593(06)05001-5.

Orf virus (ORFV) infection in a three-dimensional human skin model: Characteristic cellular alterations and interference with keratinocyte differentiation.

Muhsen M, Protschka M, Schneider L, Muller U, Kohler G, Magin T PLoS One. 2019; 14(1):e0210504.

PMID: 30699132 PMC: 6353139. DOI: 10.1371/journal.pone.0210504.

References

Yirrell D, Vestey J, Norval M . Immune responses of patients to orf virus infection. Br J Dermatol. 1994; 130(4):438-43. DOI: 10.1111/j.1365-2133.1994.tb03375.x. View

Neyts J, Snoeck R, Balzarini J, De Clercq E . Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Res. 1991; 16(1):41-52. DOI: 10.1016/0166-3542(91)90057-x. View

Murphy J, Ralfs I . Bullous pemphigoid complicating human orf. Br J Dermatol. 1996; 134(5):929-30. View

Visalli R, Courtney R, Meyers C . Infection and replication of herpes simplex virus type 1 in an organotypic epithelial culture system. Virology. 1997; 230(2):236-43. DOI: 10.1006/viro.1997.8484. View

Haig D, McInnes C, Deane D, Reid H, Mercer A . The immune and inflammatory response to orf virus. Comp Immunol Microbiol Infect Dis. 1997; 20(3):197-204. DOI: 10.1016/s0147-9571(96)00045-8. View

Haig D, Mercer A . Ovine diseases. Orf. Vet Res. 1998; 29(3-4):311-26. View

Crumbie A . The orf virus: a disease of the farming community. Community Nurse. 1998; 4(5):44-5. View

Gilray J, Nettleton P, Pow I, Lewis C, Stephens S, Madeley J . Restriction endonuclease profiles of orf virus isolates from the British Isles. Vet Rec. 1998; 143(9):237-40. DOI: 10.1136/vr.143.9.237. View

Degraeve C, De Coninck A, Senneseael J, Roseeuw D . Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cryotherapy. Dermatology. 1999; 198(2):162-3. DOI: 10.1159/000018095. View

10.

Balzarini J, Pannecouque C, Naesens L, Andrei G, Snoeck R, De Clercq E . 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids. 2004; 23(8-9):1321-7. DOI: 10.1081/NCN-200027573. View

11.

Zabawski Jr E, Cockerell C . Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol. 2000; 16(5):414-5. View

12.

Inoshima Y, Morooka A, Sentsui H . Detection and diagnosis of parapoxvirus by the polymerase chain reaction. J Virol Methods. 2000; 84(2):201-8. DOI: 10.1016/s0166-0934(99)00144-5. View

13.

Mourtada I, Le Tourneur M, Chevrant-Breton J, Le Gall F . [Human orf and erythema multiforme]. Ann Dermatol Venereol. 2000; 127(4):397-9. View

14.

Meyers C, Mane M, Kokorina N, Alam S, Hermonat P . Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology. 2000; 272(2):338-46. DOI: 10.1006/viro.2000.0385. View

15.

Nettleton P, Gilray J, Reid H, Mercer A . Parapoxviruses are strongly inhibited in vitro by cidofovir. Antiviral Res. 2001; 48(3):205-8. DOI: 10.1016/s0166-3542(00)00130-3. View

16.

Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, Vanrenterghem Y . A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol. 2001; 64(4):543-9. DOI: 10.1002/jmv.1084. View

17.

Holy A, Votruba I, Masojidkova M, Andrei G, Snoeck R, Naesens L . 6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J Med Chem. 2002; 45(9):1918-29. DOI: 10.1021/jm011095y. View

18.

Smith G, Scherba G, Constable P, Hsiao V, Behr M, Morin D . Atypical parapoxvirus infection in sheep. J Vet Intern Med. 2002; 16(3):287-92. DOI: 10.1892/0891-6640(2002)016<0287:apiis>2.3.co;2. View

19.

De Clercq E . Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002; 55(1):1-13. PMC: 9533828. DOI: 10.1016/s0166-3542(02)00008-6. View

20.

Snoeck R, Holy A, van den Oord J, De Clercq E, Andrei G . Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob Agents Chemother. 2002; 46(11):3356-61. PMC: 128754. DOI: 10.1128/AAC.46.11.3356-3361.2002. View